The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Leukemias related to treatment with DNA topoisomerase II inhibitors*
Abstract
The epipodophyllotoxins etoposide and teniposide and other DNA topoisomerase II inhibitors including anthracyclines and dactinomycin are highly efficacious anticancer drugs. All are associated with a distinct form of leukemia characterized by chromosomal translocations as a treatment complication. Most of the translocations disrupt a breakpoint cluster region (bcr) of the MLL gene at chromosome band 11q23. Other characteristic translocations also may occur. The normal function of the nuclear enzyme DNA topoisomerase II is to catalyze changes in DNA topology between relaxed and supercoiled states by transiently cleaving and re‐ligating both strands of the double helix. Anticancer drugs that are DNA topoisomerase II inhibitors are cytotoxic because they form complexes with DNA and DNA topoisomerase II. The complexes decrease the re‐ligation rate, disrupt the cleavage‐re‐ligation equilibrium, and have a net effect of increasing cleavage. The increased cleavage damages the DNA and leads to chromosomal breakage. Cells with irreparable DNA damage die by apoptosis. The association of DNA topoisomerase II inhibitors with leukemia suggests that the drug‐induced, DNA topoisomerase II‐mediated chromosomal breakage may be relevant to translocations in addition to this anti‐neoplastic, cytotoxic action. Epidemiological studies, genomic translocation breakpoint cloning and in vitro DNA topoisomerase II cleavage assays together lead to a model for treatment‐related leukemia in which DNA topoisomerase II causes chromosomal breakage and translocations form when the breakage is repaired. Med. Pediatr. Oncol. 36:525–535, 2001. © 2001 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rubinstein-Taybi syndrome caused by mutations in the transcriptional co-activator CBP
Petrif, F., Giles, R. H., Dauwerse, H. G., Saris, J. J., Hennekam, R. C. M., Masuno, M., Tommerup, N., van Ommen, G.-J. B., Goodman, R. H., Peters, D. J. M., et al. (1995) · Nature · doi:10.1038/376348a0 · Cited by 1,217
Krishnan, A., Bhatia, S., Slovak, M. L., Arber, D. A., Niland, J. C., Nademanee, A., Fung, H., Bhatia, R., Kashyap, A., Molina, A., et al. (2000) · Blood · doi:10.1182/blood.v95.5.1588.005k38_1588_1593 · Cited by 285
Nucifora, G., Birn, D., Erickson, P., Gao, J., LeBeau, M., Drabkin, H., & Rowley, J. (1993) · Blood · doi:10.1182/blood.v81.4.883.883 · Cited by 196
Cited by
Distribution and biological activities of the flavonoid luteolin
Lopez-Lazaro, M. (2009) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955709787001712 · Cited by 1,106
“Indeed, the clinical use of topoisomerase II poisons in cancer chemotherapy has been associated with an increased incidence of leukemia [241, 242].”
BackgroundThe MLL recombinome of acute leukemias in 2017
Meyer, C., Burmeister, T., Gröger, D., Tsaur, G., Fechina, L., Renneville, A., Sutton, R., Venn, N. C., Emerenciano, M., Pombo-de-Oliveira, M. S., et al. (2018) · Leukemia · doi:10.1038/leu.2017.213 · Cited by 676
The MLL recombinome of acute leukemias in 2013
Meyer, C., Hofmann, J., Burmeister, T., Gröger, D., Park, T. S., Emerenciano, M., Pombo de Oliveira, M., Renneville, A., Villarese, P., Macintyre, E., et al. (2013) · Leukemia · doi:10.1038/leu.2013.135 · Cited by 491
Topoisomerases as anticancer targets
Delgado, J. L., Hsieh, C.-M., Chan, N.-L., & Hiasa, H. (2018) · Biochemical Journal · doi:10.1042/bcj20160583 · Cited by 481
The DNA cleavage reaction of topoisomerase II: wolf in sheep's clothing
Deweese, J. E., & Osheroff, N. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkn937 · Cited by 462
DNA topoisomerase II, genotoxicity, and cancer
McClendon, A. K., & Osheroff, N. (2007) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/j.mrfmmm.2007.06.009 · Cited by 406
Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies
Azarova, A. M., Lyu, Y. L., Lin, C.-P., Tsai, Y.-C., Lau, J. Y.-N., Wang, J. C., & Liu, L. F. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0704002104 · Cited by 286
DNA Topoisomerase II in Therapy-Related Acute Promyelocytic Leukemia
Mistry, A. R., Felix, C. A., Whitmarsh, R. J., Mason, A., Reiter, A., Cassinat, B., Parry, A., Walz, C., Wiemels, J. L., Segal, M. R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042715 · Cited by 281
Self-citationMcKenney, J. K., Heerema-McKenney, A., & Rouse, R. V. (2007) · Advances in Anatomic Pathology · doi:10.1097/pap.0b013e31803240e6 · Cited by 262
Metadata
- Authors
- Felix, C. A.
- Venue
- Medical and Pediatric Oncology
- Publisher
- Wiley
- Published
- 2001-04-13
- Volume
- 36
- Issue
- 5
- Pages
- 525-535
- ISSN
- 0098-1532 (ISSN-L)
- 1096-911X
- OpenAlex
- W2082876519
- Cited by
- 191
- References
- 3
- FWCI
- 3.47
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.